Billionaire Steyer’s Farallon Is Selling Apple Inc (AAPL) and Google

FARALLON CAPITALFarallon Capital Management, which is managed by billionaire Thomas Steyer and his team, engages in just about any investment strategy dependent on fundamental analysis: pure value, event driven, merger arbitrage, and so on. It had over $21 billion under management at the end of 2011, making it one of the largest hedge funds in the world. A portion of this capital is represented by the long equity positions reported on Farallon’s 13F six to seven weeks after the close of every quarter. Read on for our evaluation of some of the fund’s investment themes and compare its activity to previous filings.

Less tech, more travel. While Farallon still owned Apple Inc. (NASDAQ:AAPL) and Google Inc (NASDAQ:GOOG) at the end of September, it sold shares of both stocks during the third quarter of the year: its Google holdings fell by about 10% and the fund sold about a third of its Apple Inc. (NASDAQ:AAPL) shares. Among the stocks that it bought in their place was travel website Priceline.com Inc (NASDAQ:PCLN); the fund increased its stake to about 250,000 shares from about 140,000 three months earlier. These transactions took place before the pullbacks in both companies’ stock prices began in earnest in October; we think that this correction has created a great buying opportunity at Apple Inc. (NASDAQ:AAPL), which is now trading at only 12 times trailing earnings despite a strong brand and high growth rates. See our continuing updates on news regarding Apple. We’re less sure of Google, which has disappointed investors with its lack of progress in integrating its acquisition of Motorola Mobility Holdings. Its earnings multiples are considerably higher, and while we’d expect the company’s growth to resume the forward P/E multiple of 14 isn’t necessarily a steal. Priceline continues to turn in strong growth rates- earnings were 27% higher last quarter than a year earlier- though it too now has a minefield ahead of it with its potential acquisition of competitor Kayak. It carries trailing and forward P/Es of 24 and 17, respectively. We’ve seen it as a potential growth stock in the past, though we worry that it may be overpaying for Kayak and that the acquisition won’t create much shareholder value.

Nexen merger arb. Nexen Inc. (NYSE:NXY) was a new holding in Farallon’s portfolio, with Steyer and his team initiating a position of 8.7 million shares. In late July the oil and gas company, which is most notable for its position in the Alberta oil sands, became a takeover target with Chinese oil company CNOOC proposing an acquisition. The deal is controversial in Canada, and approval is not yet certain (the government has set December 10th for an announcement date, though this is after a delay). The stock had been trading between $16 and $17 before the offer, and is now a bit above $24. With CNOOC’s offer for $27.50 per share, this is a merger arbitrage play that investors still have a chance to participate in (read about why hedge funds like merger arbitrage opportunities). Of course, the reason the stock is trading at a discount to the offer price is because of the possibility that the deal will be rejected, so we plan to stay clear of it ourselves.

Visa. The fund’s position in Visa Inc (NYSE:V) ticked up to 1.2 million shares from about 940,000 shares at the beginning of July. The credit card issuer has climbed 38% year to date, and its business is seeing strong improvement. According to the company’s 10-Q, revenue at Visa was up 15% in the third quarter compared to the same period in the previous year and net income nearly doubled. Investors expect strong growth at Visa, as it currently trades at 17x consensus earnings for the fiscal year ending in September 2014. We think Visa’s a great company but we wonder if it can continue to grow as rapidly as it has, and would note that other credit card companies such as Capital One and Discover are considerably cheaper.

We’re taking note of Farallon’s sale of Apple Inc. (NASDAQ:AAPL) but we still think that the drop in the stock price has created a buying opportunity at the company. We are also skeptical of the buys that the fund has made instead, as Visa and Priceline look about fairly prices (and Visa at least has peers that look to be much better values) while the Nexen deal isn’t something that we’d be confident in putting our money behind.

Biotech Insider Alert - $6 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.
Click here to Read Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 74 percentage points in 2.5 years. Our beta is only 1.2 (download a FREE newsletter and see the details inside)

Lists

Best Selling Magazines in the World

Shortest People in History

The Most Celebrated Holidays in the World

Most Expensive Handbag Brands in the World

Top Selling Comic Book Issues of this Century

The Most Powerful Women in Politics

Best Paid DJs

Most Rebellious Female Artists

Best Paid TV Actresses of 2014

Best Paid Actors of 2014

Most Expensive Horses in the World

Tallest People Ever

Most Encouraging Feminist Celebrities

Best Paid Supermodels of 2014

Top 10 Suburbs for Retirement in 2015

10 Wealthiest Cities in America

Top 10 TED Talks for Entrepreneurs

Best TED Talks on Education

25 Most Dangerous Places to Live in America

Top 10 Ski Resorts in the United States – 2014 List

Top 10 Most Remote Places in the World

Most Visited Museums in the United States

Wealthiest Photographers in the World

Most Famous Gay Athletes

The World’s Most Famous Circuses

Best Hair Stylists

Most Popular NASCAR Drivers

The Best Romance Movies of all Time

The Most Wanted Drug Lords

The Oldest Money Managers

The Greatest Directors in the World

Largest Animals in the World

World’s Most Expensive Desserts

Best Selling Comic Books of All Time

A-list Actors who Sabotaged Their Career

Rappers With a College Degree

The Best Jazz Albums of all Time

The Most Influential Jazz Musicians

The World’s Most Famous Photographers

The Best Oscar-Winning Songs

Most Influential Choreographers Ever

Most Expensive Department Stores in the World

The Most Expensive Stolen Paintings in the World

The World’s Most Expensive Teas

Top Oscar Record Holders

The Most Expensive Flowers in the World

Countries With a Booming Film Industry

Most Expensive Cupcakes in the World

Uncommon European Escapes

The Most Stolen Artists in History

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 129% in 2.5 years!! Wondering How?

Download a complete edition of our newsletter for free!